J&J-backed HistoSonics explores sale at $2.5 billion valuation, FT reports
Published by Global Banking & Finance Review®
Posted on May 2, 2025
1 min readLast updated: January 24, 2026

Published by Global Banking & Finance Review®
Posted on May 2, 2025
1 min readLast updated: January 24, 2026

HistoSonics, backed by Johnson & Johnson, is exploring a sale with a $2.5 billion valuation after receiving multiple takeover offers.
(Reuters) -HistoSonics, a medical technology company backed by Johnson & Johnson, is exploring a potential sale after receiving multiple takeover approaches, the Financial Times reported on Friday, citing people familiar with the matter.
The company is seeking a valuation of more than $2.5 billion, the report said.
(Reporting by Bipasha Dey in Bengaluru; Editing by Sonia Cheema)
The main topic is HistoSonics exploring a potential sale with a valuation of over $2.5 billion.
HistoSonics is backed by Johnson & Johnson.
HistoSonics is seeking a valuation of more than $2.5 billion.
Explore more articles in the Headlines category


